4.
How can humans be exposed to DBP?
4.1 How can workers be
exposed to DBP?
4.2 How can consumers
be exposed to DBP?
4.3 To what extent can
the general public be exposed to DBP through
the environment?
4.1
How can workers be exposed to DBP?
"Exposure assessment
Occupational exposure
Workplace exposure to
DBP
is possible due to the production of DBP,
the production of products that contain
DBP and the use of those products. Occupational
exposure levels have been estimated using
measured data and modelling by EASE with
relevant assumptions. Production of DBP
is done in closed systems. Exposure is
mainly due to activities such as filling
of tankers and drums, sampling, changing
of filters and other maintenance activities.
Typical full-shift inhalation
exposure levels in production are estimated
to be below 2 mg/m3 with a
reasonable worst case of 5 mg/m3.
Short-term inhalation exposure levels
of up to 10 mg/m3 are considered
possible. Dermal exposure in production
is expected to be highest for drumming
of DBP and was estimated by EASE to be
up to 420 mg/day.
The formulation of products
containing up to 15% of DBP
leads to inhalation exposure and dermal
exposure mainly due to adding of the substance
to mixers, mixing and forming of the products
by processes such as extruding and calendering.
Mixing and forming processes are done
at elevated temperatures (150-210°C).
The estimated reasonable worst-case full-shift
inhalation exposure level is 5 mg/m3
(typical: < 2 mg/m3, short-term
10 mg/m3). Manual addition
of DBP is estimated to lead to a dermal
exposure level of 420 mg/day.
The end use of products
containing the substance occurs in the
polymer
industry, the painting industry and the
printing industry and can be divided into
two subscenarios: aerosol
forming techniques, such as spray application,
and techniques that do not involve aerosols.
Inhalation
exposure to DBP
in techniques that do not involve aerosols
(e.g. application of a product by means
of a brush) is estimated to be negligible.
The reasonable worst-case full-shift inhalation
exposure level is estimated to be 10 mg/m3
with typical values of 2 mg/m3
and short-term exposure levels of up to
20 mg/m3. Dermal exposure during
prolonged spay application of products
containing DBP is estimated to be up to
975 mg/day. Other activities with products
containing DBP are expected to lead to
lower dermal exposure levels.
|
Scenario
|
Exposure
|
Estimated inhalation
exposure level (mg/m3)
|
Estimated skin exposure
level (mg/day) a)
|
|
Duration (hr/day)
|
Freq. (day/year)
|
Full shift (8-hour
time
weighted average)
|
Short term
|
|
Typical
|
Method b)
|
RWC
|
Method b)
|
Level
|
Method b)
|
|
Production
|
6-8
|
100-200
|
2
|
Meas.
|
5
|
Meas.
|
10
|
Expert
|
420
|
|
Production of products containing
DBP
|
6-8
|
100-200
|
2
|
Meas-
|
5
|
Meas.
|
10
|
Expert
|
420
|
|
Use of products containing DBP
- aerosol
|
6-8
|
100-200
|
2
|
Expert
|
10
|
Expert
|
20
|
Expert
|
975
|
|
- non-aerosol
|
6-8
|
100-200
|
Negl.
|
EASE
|
Negl..
|
EASE
|
Negl.
|
EASE
|
|
a)
Based on EASE dermal exposure model;
b)
Meas. = mostly based on measured data;
Expert = derived from measured data or
model results largely using expert judgement;
EASE = mostly based on results of the
EASE model
RW C Reasonable worst case negl. Negligible
Source
& © : ECB
"2003
Risk Assessment Report (RAR 003) on
Dibutyl Phthalate (DBP), Summary of the
Report,
chapter 4: Human Health
For more information,
see the full ECB Risk Assessment Report:
Chapter
4: Human Health
|